Search results
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic...
Benzinga via Yahoo Finance· 6 days agoTuesday, Novartis AG (NYSE:NVS) received FDA approval for its Lutathera (lutetium Lu 177 dotatate /...
Novartis (NVS) Lutathera Meets Primary Goal in Phase III Study
Zacks via Yahoo Finance· 7 months agoNovartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically...
Novartis bags paediatric FDA label expansion for Lutathera
Pharmaceutical Technology via Yahoo Finance· 5 days agoNovartis has received a US Food and Drug Administration (FDA) approval for the label expansion of...
Novartis details first-line data for radiopharma drug Lutathera
BioPharma Dive via Yahoo Finance· 3 months agoPhase 3 trial results showed Lutathera cut the risk of disease progression or death by 72% as...
In $4 billion deal, Bristol Myers Squibb to buy cancer therapeutics firm RayzeBio
United Press International via Yahoo News· 4 months agoDec. 26 (UPI) -- Biopharmaceutical company Bristol Myers Squibb announced Tuesday that it will...
Lilly (LLY) to Buy POINT Biopharma, Strengthen Cancer Portfolio
Zacks via Yahoo Finance· 7 months agoEli Lilly and Company LLY announced a definitive agreement to acquire cancer drugmaker POINT...
Bristol Myers to buy cancer therapy company in $4.1 billion deal
The Hill via Yahoo News· 4 months agoBristol Myers Squibb on Tuesday announced a deal to acquire RayzeBio in an effort to expand the...
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
Zacks via Yahoo Finance· 4 months agoBristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its...
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Zacks via Yahoo Finance· 3 days agoThe first-quarter 2024 earnings season picked up pace this week, with Merck MRK, Sanofi SNY,...
Lantheus-POINT Biopharma Ink Strategic Collaboration For Cancer Programs
Benzinga via Yahoo Finance· 1 year agoLantheus Holdings Inc (NASDAQ: LNTH) has licensed POINT Biopharma Global Inc's (NASDAQ: PNT) PNT2002...